CX Institutional’s Neurocrine Biosciences NBIX Stock Holding History

CX Institutional’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$21K	Hold	126	–	–	﹤0.01%	1167
2026 Q1	$17K	Buy	+126	New	+$16.7K	﹤0.01%	1161

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

CX Institutional's NBIX Position: Q2 2026 in Review

CX Institutional held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 126 shares worth $21K. The position accounts for ﹤0.01% of the portfolio, ranked #1167.

CX Institutional first reported a position in NBIX in Q1 2026 and has held it in 2 quarters since. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

CX Institutional held 126 shares of Neurocrine Biosciences worth $21K as of Q2 2026.
CX Institutional left its Neurocrine Biosciences share count unchanged in Q2 2026.
Neurocrine Biosciences made up ﹤0.01% of CX Institutional's portfolio in Q2 2026, its #1167 holding.
CX Institutional first reported a position in Neurocrine Biosciences in Q1 2026 and has held it in 2 quarters since.
777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on CX Institutional's 13F filing for Q2 2026, filed 2 Jul 2026.